In the past few years, the human population globally established a new vocabulary that includes the words “quarantine”, “self-isolation”, “pandemic” and “lockdown”. Referring to a virus that very much impacted our lives.

“Not-so-known” names of businesses became part of our routine. In this basket, we will put “Pfizer”, “Moderna”, “ AstraZeneca” and “Johnson & Johnson”. These big pharmaceutical companies are not just manufacturers of anti-covid vaccines, they have to offer significantly more. In this article, our focus will be set on Pfizer and what this progressive enterprise has to offer to the world and the market.
 

Why Pfizer?  

Pfizer is a part of the innovation process. Right now, Pfizer is prioritizing its research and development efforts in areas such as:

• Cardiovascular, metabolic, and rare disease
• Immunology and inflammation
• Neuroscience and pain
• Oncology
• Vaccines

Speaking of vaccines, Pfizer’s newest vaccine is a major highlight of their third quarter for the year 2022. They showed promising results for a vaccine targeting the respiratory syncytial virus. Respiratory syncytial virus (RSV) is a common and pervasive cause of acute respiratory illness. Each year, it is estimated that more than 177,000 older adults are hospitalized and 14,000 of them die in the United States due to RSV. Globally, there are an estimated 33 million cases of RSV annually in children less than 5 years of age, with about 3 million hospitalized and up to approximately 120,000 dying each year from complications associated with the infection.

Pfizer tested the vaccine in pregnant women. The vaccine was 81.8% protective against serious RSV for the first 90 days of their infants' lives. Pfizer's shot also proved 69.4% effective for the first six months of life. If approved, it would be the first maternal shot for RSV meant to protect newborns.

The company raised its guidance for Covid vaccine Comirnaty by $2 billion to $34 billion and reiterated expectations for $22 billion from the antiviral pill Paxlovid.

In addition to that, Pfizer plans to launch 19 new products or new uses for existing drugs in the next 18 months.

Q3 Results

On the 1st of November, this U.S. pharmaceutical and biotechnological corporation published its results for Q3. We are happy to say that they beat Wall Street’s expectations.

Pfizer posted 10.17 billion U.S. dollars of adjusted income in the third quarter, which grew 40 percent year on year. Earnings per share (EPS) stood at 1.78 dollars, beating the market expectation of 1.39 dollars per share.

Pfizer's third-quarter revenues plunged 6 percent year on year to 22.6 billion dollars, but higher than 21 billion dollars of the average previously estimated by Refinitiv.

Compared to the same period last year, sales fell due to lowering demand for its Covid vaccines internationally. The company sold $4.4 billion of its vaccine worldwide in the quarter, a decrease of 66% compared with the third quarter of 2021.

Sales are expected to rise almost 4% to $24.75 billion in the fourth quarter. Analysts polled by FactSet also call for adjusted earnings of $1.33 per share, up 23%.

Stock News that might have an impact

Pfizer not too long ago launched a Phase 3 study of its messenger RNA-based flu shot. The study will contain 25,000 adults in the U.S. The messenger RNA, or mRNA, or this flu shot will be based on the same technology that is hidden behind the Covid vaccine.

Another event that might influence Prizer stock is that Pfizer and its partner, Myovant Sciences (MYOV), gained U.S. approval for Myfembree known as a once-daily pill for moderate to severe endometriosis. In the final test, the drug cut menstrual pain while reducing average bone mineral density loss by less than 1%.

But Pfizer recently terminated a study of an experimental cardiomyopathy drug. An interim analysis suggested the drug was unlikely to meet its goals in the Phase 3 study.

Pfizer is also working to expand beyond Covid with mRNA technology. It has a gene-editing deal with Beam Therapeutics (BEAM) and deals with Codex DNA (DNAY) and privately held Acuitas Therapeutics to bolster mRNA efforts.

PFE Stock Outlook

Looking back in time on 01.06.2022 Pfizer’s stock was valued at around 59$. The Pfizer 52-week high stock price is valued at 61.71, which is 31.1% above the current share price. The lowest point was on 11.10.2022 at around 41$. Currently, the stock is valued at 47.60$ and is showing some signs of recovery. According to 18 analysts, 12-month price forecasts for Pfizer have a median target of 52.65, with a high estimate of 75.00 and a low estimate of 44.00. The median estimate represents a +10.61% increase from the last price of 47.60$.

Conclusion

In recent years the pharmaceutical manufacturer Pfizer dominated the global markets, but there are no concerns; Pfizer will continue to grow. Their CEO Albert Bourla presented his plan on the 1st of November to keep the pharmaceutical giant growing through 2030, as the Covid-19 pandemic is going away for good. Bourla told analysts that Pfizer plans to add $25 billion to the company’s revenues by 2030 through recent acquisitions as well as the development of its in-house drug and vaccine pipeline. He highlighted three key areas of concern — respiratory syncytial virus, migraines, and ulcerative colitis.

Hopefully, if Pfizer manages to outgrow the estimated numbers its stock will potentially explode. This brings out positive opportunities for traders and investors. But don’t worry, even if Pfizer's stock fails to grow, you can always profit from its price movements with CFD trading.